New York, Oct. 25, 2017 -- According to a recent market report published by Persistence Market Research titled “Clinical Communication and Collaboration Market: Global Industry Analysis (2012–2016) and Forecast (2017–2025),” revenue from the global clinical communication and collaboration market was US$ 138.5 Mn in 2012 and US$ 214.8 Mn in 2016, representing a CAGR of 11.6% from 2012 to 2016. This revenue growth is attributed to addition of new features in clinical communication and collaboration solutions. Persistence Market Research forecasts revenue from the global clinical communication and collaboration market to increase from US$ 249.4 Mn in 2017 to US$ 861.6 Mn by 2025 end, representing a CAGR of 16.9% from 2017 to 2025. This increasing revenue growth is attributed to continuous launch of new clinical communication and collaboration solutions and option for customization supporting growth of this market.
Advancement in patient monitoring technologies and need for seamless communication among hospital staff are major factors driving revenue growth of the global clinical communication and collaboration market. However high initial costs and disruption of workflows are restraining revenue growth of the clinical communication and collaboration market.
Request a PDF Sample at https://www.persistencemarketresearch.com/samples/13042
Global Clinical Communication and Collaboration Market: Segmentation & Forecast
The global clinical communication and collaboration market is categorized on the basis of Component (Software, Services), Content Type (Text, Voice, Video), end user (Clinical Laboratories, Hospitals, Physicians, Others), and Region (North America, Latin America, Europe, Asia Pacific and Middle East and Africa).
- By component, revenue generation from the Services segment is expected to increase at a high CAGR of 19.1% over the forecast period. In terms of value, the Services segment is anticipated to increase 3.9X between 2017 and 2025. The Services segment is expected to register high Y-o-Y growth rates throughout the forecast period. In terms of value, the Software segment is projected to be the most attractive in the global clinical communication and collaboration market during the forecast period.
- By content type, the Video segment is expected to register high Y-o-Y growth rates throughout the forecast period. In terms of value, this segment is expected to expand at a CAGR of 18.4% during the forecast period. In terms of value, the Text segment is projected to be the most attractive in the global clinical communication and collaboration market during the forecast period.
- By end user, the Hospitals segment is projected to be the most attractive segment in terms of value in the global clinical communication and collaboration market during the forecast period. The Physicians segment is expected to register high Y-o-Y growth rates throughout the forecast period. In terms of value, this segment is expected to expand at a CAGR of 17.2% during the forecast period.
- By region, the Asia Pacific regional market is expected to register high Y-o-Y growth rates throughout the forecast period. In terms of value, APAC is expected to expand at a CAGR of 18.8% during the forecast period. In terms of value, the APAC market is anticipated to increase 3.8X between 2017 and 2025. Clinical communication and collaboration solution providers can focus on expanding across several countries in APAC region such as India, China.
View Report Table of Contents, Figures, and Tables
Vendor Insights
The report profiles some of the leading companies operating in the global clinical communication and collaboration market such as VOCERA COMMUNICATIONS, INC., TIGERTEXT, Cisco Systems Inc., and Jive Software, Inc.
Popular Reports by Persistence Market Research:
- Global Market Study on Consumer Mobile Payments: https://www.persistencemarketresearch.com/market-research/consumer-mobile-payments-market.asp
- Enterprise Social Networks and Online Communities Market: https://www.persistencemarketresearch.com/market-research/enterprise-social-networks-and-online-communities-market.asp
Persistence Market Research Overview
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research U.S. Sales Office: 305 Broadway, 7th Floor New York City, NY 10007 +1-646-568-7751 United States USA - Canada Toll-Free: 800-961-0353 Email: [email protected]


Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Washington Post Publisher Will Lewis Steps Down After Layoffs
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



